EUVIMED · CrossrefZeitschrift
Blood Neoplasia
ISSN 2950-3280 · Elsevier BV
Neueste Artikel
Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms
Deuterium labeling uncovers deregulated myeloid cell kinetics in chronic myelomonocytic leukemia
Increased severe neurotoxicity and hospital stay in octogenarians receiving CAR T-cell therapy for large B-cell lymphoma
Rosai-Dorfman disease: a 30-year institutional study of clinical features, treatment patterns, and outcomes
A long-term population-based study of lymphoplasmacytic lymphoma and Waldenström macroglobulinemia in Ontario, Canada
Adkins J, Zhao C. Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms. Blood Neoplasia. 2026;3(4):100265.
Circulating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies
PLK4 inhibition by CFI-400945 triggers polyploidy and synergistic apoptosis with venetoclax in TP53-mutant AML
Dual EZH2 & Histone Deacetylase Inhibition Suppresses Cell Viability in Down Syndrome Myeloid Leukemia by Depleting EZH2
Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models
Prospective Analyses of the Utility of Liquid Biopsy in Patients with Fever of Unknown Origin Suspected of Lymphoma
Disrupting RNA Splicing Sensitizes T-ALL Cells to Proteasome Blockade
Out-of-frame but not out-of-function: cryptic mRNA splicing in FLT3 internal tandem duplications
Prognostic and Serial Assessment of Functional/Psychosocial Factors in Older Adults Receiving AML Induction Chemotherapy
Resistance to CD20×CD3 Bispecific Antibodies in B-Cell Lymphoma: Mechanisms and Emerging Therapeutic Strategies
Unmasking BCL2A1: IL10/STAT3-Driven BCL2A1 Expression Promotes Apoptosis Resistance in DLBCL
Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma
Safety Outcomes of First-Line Venetoclax vs Second-Generation BTKi in CLL/SLL: A Retrospective Cohort Study
Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
EZH2-driven immune evasion at disease presentation defines high-risk t(16;21) FUS::ERG pediatric AML
AML/MDS patients with DDX41 (DEAD-box helicase 41) germline variants: A single-center experience
Dasatinib-based induction and blinatumomab + TKI consolidation/maintenance for BCR::ABL1+ ALL: BLISSPhALL Study Results
Long-read cDNA sequencing reveals novel isoforms and spliceosome mutant-enriched transcripts in AML and MDS cells
Trends in Survival of Marginal Zone Lymphoma by Treatment Era in the United States
Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia
Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21
ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma
Menin inhibitors as a treatment for acute leukemia: from bench to the clinic
Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia
Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis
EUVIMED